AZN vs KNSA

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

KNSA exhibits strong deterministic health with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.02), yet it faces a severe valuation disconnect. The current price of $47.08 trades at a massive premium to its Graham Number ($11.20) and Intrinsic Value ($5.25), suggesting the market is pricing in aggressive future growth. While revenue growth is impressive at 65% YoY, the company has missed earnings estimates in 4 consecutive quarters with an average surprise of -35.29%. This fundamental instability, coupled with heavy C-suite insider selling and a bearish technical trend, offsets the strong financial health.